DSV Panalpina A/S
Company Announcement No. 861
"Despite the COVID-19 pandemic and unpredictability throughout the year, 2020 was another strong year for DSV Panalpina. Thanks to an extraordinary effort by our staff, we delivered excellent results across all our divisions and markets. We completed the Panalpina integration and achieved an operating profit before special items of DKK 9,520 million, which is a significant increase of 47% compared to 2019. 2021 will be another challenging year, but with our strong and flexible business model and the right people on board, we will make sure to keep our customers’ supply chains flowing," says Jens Bjørn Andersen, CEO.
Selected financial highlights for 2020 (1 January - 31 December 2020)
(DKKm) | Q4 2020 | Q4 2019 | Full-year 2020 | Full-year 2019 |
Revenue | 31,716 | 30,122 | 115,932 | 94,701 |
Gross profit | 7,212 | 7,084 | 28,534 | 23,754 |
EBIT before special items | 2,616 | 1,784 | 9,520 | 6,654 |
Special items | 685 | 609 | 2,164 | 800 |
Operating margin | 8.2% | 5.9% | 8.2% | 7.0% |
Conversion ratio | 36.3% | 25.2% | 33.4% | 28.0% |
Adjusted earnings | 6,146 | 4,456 | ||
Adjusted free cash flow | 8,746 | 3,678 | ||
Diluted adjusted earnings per share of DKK 1 | 26.5 | 22.1 | ||
Proposed dividend per share (DKK) | 4.00 | 2.50 | ||
EBIT before special items | ||||
Air & Sea | 1,790 | 1,195 | 7,026 | 4,506 |
Road | 420 | 272 | 1,390 | 1,251 |
Solutions | 456 | 340 | 1,161 | 1,013 |
Q4 2020 results
For Q4 2020, revenue amounted to DKK 31,716 million (Q4 2019: DKK 30,122 million). The growth of 10.5% (in constant currencies) was mainly driven by increased freight rates. Q4 2020 is the first quarter with full impact of the Panalpina acquisition on comparative figures.
For Q4 2020, gross profit came to DKK 7,212 million (Q4 2019: DKK 7,084 million). The growth in gross profit came to 6.6% (in constant currencies) for the Group and was driven by good performance in all three divisions.
EBIT before special items was up by 54.6% (in constant currencies) to DKK 2,616 million for Q4 2020 (Q4 2019: DKK 1,784 million). All three divisions contributed to the growth, which was supported by strong cost discipline and the impact from Panalpina integration synergies.
Dividend
The Board of Directors proposes ordinary dividends of DKK 4.00 per share for 2020 (2019: DKK 2.50 per share).
Outlook for 2021
- EBIT before special items is expected to be in the range of DKK 10,500-11,500 million.
- The effective tax rate of the Group is expected to be approximately 23%.
The 2021 outlook assumes a stable development in the markets in which we operate and a continued gradual recovery of the global economy after the COVID-19 crisis.
Share buyback – increase of current programme
A separate company announcement about an increase of the current share buyback programme of DKK 2,000 million will be issued today. This means that the maximum aggregate purchase price of the shares to be bought back is increased to DKK 8,000 million. The programme will run until 30 April 2021.
New 2025 financial targets
After the integration of Panalpina, the following 2025 financial targets have been set for the Group and for each division.
Long-term financial targets
2025 targets (%) | 2020 | 2025 targets |
DSV Panalpina Group | ||
Conversion ratio | 33.4 | >40.0 |
ROIC (before tax) | 14.3 | >20.0 |
Divisional targets for conversion ratio | ||
Air & Sea | 41.6 | >47.5 |
Road | 22.6 | >30.0 |
Solutions | 21.6 | >30.0 |
Investor teleconference
DSV Panalpina will host an investor teleconference on 10 February 2021, at 13.00 CET. Please refer to investor.dsv.com for details.
Contacts
Investor Relations
Flemming Ole Nielsen, tel. +45 43 20 33 92, flemming.o.nielsen@dsv.com
Frederikke Anna Linde, tel. +45 43 20 31 95, frederikke.a.linde@dsv.com
Mads Kristian Hofmeister, tel. +45 43 20 33 88, madskristian.hofmeister@dsv.com
Media
Maiken Riise Andersen, tel. +45 43 20 30 74, maiken.r.andersen@dsv.com
Yours sincerely,
DSV Panalpina A/S
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV28.4.2025 08:30:00 CEST | Press release
ONWARD Medical Announces Release of 2024 Annual Report
Purespring Therapeutics28.4.2025 08:00:00 CEST | Press release
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
FreeMove Alliance28.4.2025 08:00:00 CEST | Press release
FreeMove Alliance and du cooperate to better serve Multinationals in the United Arab Emirates
LIfT BioSciences28.4.2025 08:00:00 CEST | Press release
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
Fingerprint Cards AB28.4.2025 08:00:00 CEST | Press release
Mantra Softech extends licence for FPC iris technology to expand into new markets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom